Literature DB >> 17312351

Progression of coronary artery calcification in predialysis patients.

Domenico Russo1, Salvatore Corrao, Ida Miranda, Carolina Ruocco, Simona Manzi, Rosanna Elefante, Diego Brancaccio, Mario Cozzolino, Maria L Biondi, Vittorio E Andreucci.   

Abstract

BACKGROUND: In patients on dialysis coronary artery calcification (CAC) rapidly proceeds due to impaired mineral metabolism and/or exogenous calcium load. Progression has not been assessed in patients with chronic kidney disease not yet requiring dialysis (CKD patients). In this study, rate and determinants of CAC progression have been evaluated in CKD patients who are exposed to minor derangement of mineral metabolism and calcium load.
METHODS: Consecutive patients were enrolled. Exclusion criteria were: symptomatic coronary disease, arrhythmia, myocardial infarction, and diabetes. Serum calcium, phosphorus, parathyroid hormone, homocysteine, C-reactive protein, triglycerides, total cholesterol, high- and low-density lipoprotein cholesterol were serially measured. Fetuin-A was assessed at entry into the study. CAC progression was detected by measuring total calcium score (TCS) with computed tomography. Initial and final scans were obtained. Predictive factors of progression were investigated.
RESULTS: Fifty-three patients had CKD (stage 3-5 CKD; K-DOQI classification) not yet requiring dialysis, and 60 patients had normal renal function (NRF patients). Follow-up lasted 24 +/- 4.2 months (mean +/- SE). Patients with CAC were older with lower serum fetuin-A. TCS increased from 73 +/- 17 to 80 +/- 20 (mean +/- SE; p = NS) in NRF patients, and from 384 +/- 116 to 602 +/- 140 (mean +/- SE; p < 0.01) in CKD patients. Serum phosphorus [OR = 1.97 (1.14-3.41, 95% CI); p = 0.015] was the only variable that was associated with CAC progression. Cardiovascular events occurred in CKD patients with CAC.
CONCLUSION: CAC progression was prominent in CKD patients and correlated with serum phosphorus. Fatal and nonfatal cardiovascular events were more frequent in CKD patients. Studies are required to ascertain whether the attainment of serum phosphorus concentration lower than that suggested by current guidelines may reduce CAC progression and ultimately mortality. Copyright 2007 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2007        PMID: 17312351     DOI: 10.1159/000100044

Source DB:  PubMed          Journal:  Am J Nephrol        ISSN: 0250-8095            Impact factor:   3.754


  23 in total

1.  Treatment options of secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease stages 3 and 4: an historic review.

Authors:  Piergiorgio Bolasco
Journal:  Clin Cases Miner Bone Metab       Date:  2009-09

2.  Risk factors: Calcium supplements and cardiovascular risk.

Authors:  Ian R Reid; Mark J Bolland
Journal:  Nat Rev Cardiol       Date:  2012-07-10       Impact factor: 32.419

3.  Ferric citrate hydrate for the treatment of hyperphosphatemia in nondialysis-dependent CKD.

Authors:  Keitaro Yokoyama; Hideki Hirakata; Takashi Akiba; Masafumi Fukagawa; Masaaki Nakayama; Kenichi Sawada; Yuji Kumagai; Geoffrey A Block
Journal:  Clin J Am Soc Nephrol       Date:  2014-01-09       Impact factor: 8.237

Review 4.  The role of fetuin-A in mineral trafficking and deposition.

Authors:  Michael M X Cai; Edward R Smith; Stephen G Holt
Journal:  Bonekey Rep       Date:  2015-05-06

5.  Vascular calcification is not related to serum fetuin-A and osteopontin levels in hemodialysis patients.

Authors:  O Ulutas; M C Taskapan; A Dogan; T Baysal; H Taskapan
Journal:  Int Urol Nephrol       Date:  2017-11-13       Impact factor: 2.370

Review 6.  Noninvasive imaging for assessment of calcification in chronic kidney disease.

Authors:  Cristina Karohl; Luis D'Marco Gascón; Paolo Raggi
Journal:  Nat Rev Nephrol       Date:  2011-08-23       Impact factor: 28.314

7.  A Randomized Trial of Magnesium Oxide and Oral Carbon Adsorbent for Coronary Artery Calcification in Predialysis CKD.

Authors:  Yusuke Sakaguchi; Takayuki Hamano; Yoshitsugu Obi; Chikako Monden; Tatsufumi Oka; Satoshi Yamaguchi; Isao Matsui; Nobuhiro Hashimoto; Ayumi Matsumoto; Karin Shimada; Yoshitsugu Takabatake; Atsushi Takahashi; Jun-Ya Kaimori; Toshiki Moriyama; Ryohei Yamamoto; Masaru Horio; Koichi Yamamoto; Ken Sugimoto; Hiromi Rakugi; Yoshitaka Isaka
Journal:  J Am Soc Nephrol       Date:  2019-04-29       Impact factor: 10.121

8.  Pulse pressure and presence of coronary artery calcification.

Authors:  Domenico Russo; Luigi F Morrone; Stefania Brancaccio; Paola Napolitano; Ermanno Salvatore; Rosanna Spadola; Massimo Imbriaco; Cinzia V Russo; Vittorio E Andreucci
Journal:  Clin J Am Soc Nephrol       Date:  2009-02       Impact factor: 8.237

9.  Administration of alfacalcidol for patients with predialysis chronic kidney disease may reduce cardiovascular disease events.

Authors:  Sachiyo Sugiura; Daijo Inaguma; Akimitsu Kitagawa; Minako Murata; Yutaka Kamimura; Sho Sendo; Kyoko Hamaguchi; Hiroshi Nagaya; Miho Tatematsu; Kei Kurata; Yukio Yuzawa; Seiichi Matsuo
Journal:  Clin Exp Nephrol       Date:  2009-10-31       Impact factor: 2.801

Review 10.  Pharmacological Management of Secondary Hyperparathyroidism in Patients with Chronic Kidney Disease.

Authors:  S N Salam; A Khwaja; M E Wilkie
Journal:  Drugs       Date:  2016-05       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.